Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Breast Cancer Adjuvant Hormonotherapy : Tamoxifen and the Anti-aromatases Pharmacokinetics, Correlation With the Pharmacogenetic Characteristics PHACS Protocol : Pharmacology of Adjuvant Hormonotherapy in Breast Cancer

NCT01127295 is registered in ClinicalTrials.gov with Institut Claudius Regaud as lead sponsor.

NCT NCT01127295
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01127295 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Breast Cancer Adjuvant Hormonotherapy : Tamoxifen and the Anti-aromatases Pharmacokinetics, Correlation With the Pharmacogenetic Characteristics PHACS Protocol : Pharmacology of Adjuvant Hormonotherapy in Breast Cancer
Lead sponsor
Institut Claudius Regaud
Phase
Phase 4
Overall status
Completed
Start date
June 17, 2010
Completion date
December 1, 2017
Enrollment
2,000 (actual)
Sites
24

Conditions

As the registry lists them; a condition with its own page is linked.

hormono-depending adjuvant breast cancer